الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 93 |  |  |
| | | from | 93 | | |
Abstract
Over the past decade, there has been concentration on detecting adequate lines of immunological therapy targeting AML, particularly for targeting leukemic cells and their progenitors. But,the prognosis of acute myeloid leukemia (AML) patients is still inferior,despite recent approval of new promising targeted therapies.
CD123(alpha subunit of the interleukin 3 receptor) is a cell membrane protein highly expressed in many malignancies in haematology that makes it a promising therapeutic target.
CD123 overexpression causes increased number and increased survival, in addition to egress of hematopoietic cells from bone marrow.
Using a therapeutic monoclonal antibody to target the interleukin‐3 receptor alpha chain (CD123), might stop survival, proliferation, and differentiation of cells and other properties controlled by the IL‐3 receptor .
Effectivness of therapies targeting CD123 in acute leukemia is shown to be related to CD123 presence on leukemic cells, as was detected for other therapies.
Our study aimed to study inteleukin-3 receptor (CD123) expression in acute myeloid leukaemia in Egyptian adult newly diagnosed acute myeloid leukemia patients (older than 18 years).Also, to find out its relation to disease characteristics and to detect its impact on response to induction chemotherapy
The present study was conducted on sixty four newly diagnosed AML patients admitted to the Haematology Unit, Internal Medicine Department, Alexandria Main University Hospital in the period from January 2022 to December 2022.
All submitted patients were diagnosed by performing bone marrow aspiration and immunophenotyping, as well as undergoing routine chemical testing, and conventional karyotyping. Molecular tests (FLT3 gene mutation, NPM1 gene mutation) was done for selected cass. Bone marrow samples were also tested for CD123 marker expression by flowcytometry.
CD 123 values less than 20 percent were considered negative , while values more than or equal 20 were considered positive for CD 123.
All patients included in the study received induction chemotherapy which included, cytarabine 100-200 mg/m2 x 7days with daunorubicin 60-90 mg/m2 x3 days.
After recovery from chemotherapy induced bone marrow aplasia (day 28), patients were evaluated for response to therapy by bone marrow aspiration.
Patients were divided into two groups depending on response to induction chemotherapy.
Responders included patients who achieved complete remission following induction chemotherapy.
Non responders included patients who didn’t achieve complete remission following induction chemotherapy.
At diagnosis 21 patients (32.8%) were negative for CD 123 , while 43 patients (67.2%) were positive for the marker ( the majority).
After receiving induction chemotherapy, 22 patients(34.4%) achieved complete remission (responders),while 42 patients (65.6%) were non responders.
Comparing responders and non responders, there was a statistically significant higher number of CD123 positive patients in non responders compared to responder group.Also, both median and mean values of CD123 were statistically significant higher in non responders compared to responders.
There was a statistically significant relation between combinations of FLT3 and NPM mutations and CD123% with the highest level of CD123 in the group showing mutation in both FLT3 and NPM. However,There was no statistically significant correlation between CD123% and bone marrow blast % in the present study.